GENERAL ANESTHESIA DRUGS MARKET ANALYSIS

The global general anesthesia drug market is estimated to be valued at US$ 4.95 Billion in 2023 and is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030).

Analysts’ Views on the Global General Anesthesia Drug Market:

 General anesthesia drugs are used during surgical procedures to induce unconsciousness to patients by the inhibition of sensory, motor, and sympathetic nerve transmission at the level of the brain that results in unconsciousness and lack of sensation and incapable to feel painful stimuli while controlling involuntary reflexes. The rising number of geriatric and patient population with increase surgical procedures for chronic disorders like cardiovascular Diseases (CVD), cancer, and lung disorders and also open surgeries such as plastic surgery, orthopedics, obstetrics & gynecology, and others. Thus, it offers the opportunity for various manufacturers to offer innovative anesthesia drugs that allows surgeons to perform such surgeries more efficiently.

Figure 1. Global Anesthesia Drug Market Share (%), By Route of Administration, 2023

To learn more about this report, request sample copy

Global Anesthesia Drug Market - Drivers

• Increasing prevalence of chronic disorders treatment with minimal Invasive surgery (MIS): Increasing number of chronic disorders like cardiovascular diseases, lung diseases, and cancer, and increasing advancements in surgeries like minimal invasive surgeries are expected to propel the growth of the global anesthesia drug market over the forecast period. For instance, an article published in the Minimal Invasive Surgery Journal (MIS journal) reported 58 papers were accepted and published on minimal invasive surgery (MIS), that included 37 reviews, 10 original articles, and one systematic review high-quality paper were accepted for research purposes published in MIS journal, including 37 reviews, 10 original articles. Systematic review included computer assisted quality assessment for surgeries, Commissural alignment in transcatheter aortic valve implantation which can be a new frontier to facilitate coronary re-access and Redo transcatheter aortic valve implantation (TAVI) in hepatocellular carcinoma.

Figure 2. Global Anesthesia Drug Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Anesthesia Drug Market - Regional Analysis

North America dominates the general anesthesia drug industry and is expected to dominate over the estimated period. The U.S. is the world's largest regional market. The outbreak of COVID-19 resulted in severe shortages of anesthesia medicines, including dexmedetomidine, midazolam, propofol, and neuromuscular blocking agents. As a result, numerous corporations are increasing anesthetic medicine production. For instance, Hikma Pharmaceutical a U.K. based multinational pharmaceutical company, redeveloped a medicine, "Propofol Injectable Emulsion," in May 2020," in the U.S. and in July 2022, Cosmo pharmaceuticals, a global pharmaceutical company,  announced that the U.S. Food and Drug Administration (FDA) approved BYFAVO (Remimazolam), a  novel benzodiazepine for intravenous anesthetics approved for used as procedural sedation and general anesthesia

Global Anesthesia Drug Market - Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as the U.S., China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.
• However, the COVID-19 pandemic had a negative impact on the global anesthesia drug market, resulting in surgeries being postponed or canceled and usage of general anesthesia drugs post COVI reduces due to its impact on COVID drugs. For instance, in February 2023 an article published by European Review for Medical and Pharmacological Sciences reports that patients has increased risk in post-operative death and pulmonary complications for at least six weeks after symptomatic and asymptomatic COVID-19 infection as receiving various drug therapy for COVID-19 or had received in the recent past are not feasible for a safe interval before surgical intervention after contacting COVID-19. As anti-COVID-19 drugs may also interact with anesthetic and analgesic drugs. However, as activities resume, all of the elective surgeries that had been postponed are now being completed, increasing anesthesia drug consumption.

Global Anesthesia Drug Market Segmentation:

The global anesthesia drug market report is segmented based on drug molecule, route of adminitration, end user, and by region.

• By drug molecule , the market is segmented into Desflurane, Isoflurane, Sevoflurane, Propofol, Etomidate, Methohexital, Thiopentone, Midazolam, and Ketamine. Out of which, the propofol drug is expected to hold a dominant position in the global anesthesia drug market during the forecast period, and this is attributed to research and development for modification to improve the pharmacodynamic, pharmacokinetic, and side effect properties of propofol drug molecule.
• By route of adminitration, the market is segmented into intravenous anesthesia and inhalation anesthesia. Out of which, Intravenous Anesthesia is expected to dominate the market over the forecast period and this is attributed to increasing R&D and lesser known side effects causing by these drugs.
• By end user, the market is segmented into hospitals, clinics, and ambulatory surgical centers. Out of which,  hospitals is expected to dominate the market over the forecast period, and this is attributed to the prompt treatment that can lead to proper recovery.
• By Region, the market is segmented into hospitals, clinics, and ambulatory surgical centers. Out of which,  hospitals is expected to dominate the market over the forecast period, and this is attributed to the prompt treatment that can lead to proper recovery

Among all the segmentation, the drug molecule segment is expected to dominate the market over the forecast period and this is attributed to increasing preference and usage of propofol drug molecule all over the globe.

Global Anesthesia Drug Market - Cross Sectional Analysis:

Key players are making  development of anesthesia drug and regulations of these drugs are emerging economies is also expected to boost demand of general anesthesia drug market in North America region. For instance, in May 2020, Hikma Pharmaceuticals PLC, a multinational generic drug pharmaceutical company, got quick approval from U.S. Food and Drug Administration (FDA) approval for propofol injectable emulsions during the COVID-19 outbreak, as there was surge in the demand for propofol as it was being used to as a sedative for the COVID-19 patients who were ventilated.

Global Anesthesia Drug Market: Key Developments

In April 2022, GE Healthcare, a U.S.-based multinational healthcare and medical technology company,  received the U.S. Food and Drugs Approval (FDA) pre-market approval (PMA) for its End-tidal (Et) control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System. The device is to have a direct control of the end-tidal concentration that reflects the drug level in the patient’s blood along with that low-flow anesthesia has benefits for hospitals and the environment.

In September 2021, Medical University of Vienna had positive results from Phase IV for ADV6209 which is a new oral Midazolam formulation, on preoperative anxiety and sedation levels in paediatric anaesthesia.

In May 2021, Heron Therapeutics, Inc., a multinational  biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for ZYNRELEF, which is indicated in adults for soft tissue to produce postsurgical analgesia for up to 72 hours after small-to-medium open abdominal, foot and ankle, and lower extremity total joint arthroplasty surgical procedures.

Global Anesthesia Drug Market: Key Trends

• Introduction of  anesthesia drug with advanced technology: The introduction of  anesthesia drugs with advanced technology in the market is expected to drive the growth of the global anesthesia drug market over the forecast period. For instance, in February 2022, Massachusetts Institute of Technology (MIT), a private land-grant research university in Massachusetts, U.S. and Massachusetts General Hospital (MGH), demonstrated a study on machine learning algorithm for continuously automated dosing of the general anesthesia drug propofol by using an application of deep reinforcement learning, in which the neural networks of the software’s learned how its dosing choices maintain unconsciousness and how to analyse the efficacy of its own actions. The algorithm of the system advances increase the feasibility for computers to maintain patient unconsciousness with lesser drug and no requirement of constant monitoring of healthcare professional.

Global Anesthesia Drug Market: Restraint

• Disadvantages associated with side effects: Use of general anesthesia drugs anesthetics may cause side effects such as nausea, vomiting sore throat, and irritation in the respiratory system, neurotoxicity to a certain extent, affecting brain development or causing cognitive impairment, which is expected to hinder the growth of the global general anesthesia drugs market. For instance, in August 2022, an article published in world  journal of clinical cases, Jinmei Song et al published his finding that patients showed hysterical somatic disorders during general anesthesia induced by propofol combined with lidocaine. General anesthesia caused to increased hemodilution due to infusion of crystalloid solution that caused changes in plasma volume. It can also affect hemodynamics, which resulted in a series of perioperative complications, most commonly cardiopulmonary. It causes kidney injury with affecting the excretion of anesthetic metabolites, and use of general anesthetics may lead to adverse renal outcomes.

Global AnesthesiaAnesthesia Drug Market - Key Players

The major players operating in the global anesthesiaanesthesia drug market include Baxter Healthcare, Dr. Reddy's Laboratories, Fresenius Kabi, Pfizer Inc., Hikma Pharmaceuticals, Sagent Pharmaceuticals, Teva Pharmaceuticals, Par Pharmaceutical, Viatris Inc., AbbVie, Piramal Critical Care, Aspen Global Incorporated, B. Braun SE, Abbott, COSMO PHARMACEUTICALS, Hospira Inc., Maruishi, Hengrui, and Lunan.

*Definition: General anesthesia drugs are used during surgical procedures to induce unconscious to patient by inhibition of sensory, motor, and sympathetic nerve transmission at the level of the brain that results in unconsciousness and lack of sensation and incapable to feel painful stimuli while controlling involuntary reflexes.